company background image
SFA

Sopharma AD BUL:SFA Stock Report

Last Price

лв4.50

Market Cap

лв547.8m

7D

0.4%

1Y

32.4%

Updated

12 Aug, 2022

Data

Company Financials +
SFA fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance4/6
Financial Health5/6
Dividends0/6

SFA Stock Overview

Sopharma AD researches and develops, produces, and trades in medicinal substances, finished drug forms, veterinary vaccines, infusion solutions, and plastic medical disposable products for human and veterinary medicine, and food supplements in Bulgaria and internationally.

Sopharma AD Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sopharma AD
Historical stock prices
Current Share Priceлв4.50
52 Week Highлв4.80
52 Week Lowлв3.40
Beta0.17
1 Month Change3.69%
3 Month Change3.21%
1 Year Change32.35%
3 Year Change35.95%
5 Year Change-8.56%
Change since IPO-27.27%

Recent News & Updates

Shareholder Returns

SFABG PharmaceuticalsBG Market
7D0.4%-3.0%0.4%
1Y32.4%-1.0%8.8%

Return vs Industry: SFA exceeded the BG Pharmaceuticals industry which returned -1% over the past year.

Return vs Market: SFA exceeded the BG Market which returned 8.8% over the past year.

Price Volatility

Is SFA's price volatile compared to industry and market?
SFA volatility
SFA Average Weekly Movement2.3%
Pharmaceuticals Industry Average Movement5.7%
Market Average Movement5.2%
10% most volatile stocks in BG Market8.9%
10% least volatile stocks in BG Market2.5%

Stable Share Price: SFA is less volatile than 75% of BG stocks over the past 3 months, typically moving +/- 2% a week.

Volatility Over Time: SFA's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19334,790Ognian Donevhttps://www.sopharmagroup.com

Sopharma AD researches and develops, produces, and trades in medicinal substances, finished drug forms, veterinary vaccines, infusion solutions, and plastic medical disposable products for human and veterinary medicine, and food supplements in Bulgaria and internationally. It offers products in various therapeutic areas, such as cardiology, gastroenterology, pain management, cough and cold, immunology and dermatology, respiratory and asthma, neurology and psychiatry, urology, and gynecology. The company’s products comprise Carsil to treat gastroenterological disorders; Tempalgin, an analgesic; Tabex, a plant-based drug used for smoking secession; Tribestan, a plant-based drug used for stimulation of functions of the sexual system; Broncholytin, which is used to suppress cough; Analgin, a generic analgesic; Nivalin, a plant-based product used for diseases of the peripheral nervous system; and Methylprednisolon, a general medicine for cases of severe allergies and life-threatening conditions.

Sopharma AD Fundamentals Summary

How do Sopharma AD's earnings and revenue compare to its market cap?
SFA fundamental statistics
Market Capлв547.84m
Earnings (TTM)лв92.04m
Revenue (TTM)лв1.63b

6.0x

P/E Ratio

0.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SFA income statement (TTM)
Revenueлв1.63b
Cost of Revenueлв1.28b
Gross Profitлв352.27m
Other Expensesлв260.23m
Earningsлв92.04m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Jan 30, 2023

Earnings per share (EPS)0.76
Gross Margin21.62%
Net Profit Margin5.65%
Debt/Equity Ratio35.5%

How did SFA perform over the long term?

See historical performance and comparison